Bio-chromatography company Sartorius BIA Separations (BIA) and exosomes medicines company Exopharm have signed a Material Transfer Agreement and associated collaborative programme.
The partnership aims to combine Exopharm’s LEAP technology together with BIA’s CIM (Convective Interaction Media) monolith chromatography for improved large-scale therapeutic exosome production and commercialisation.
The companies hope to meet the demand for a large-scale, high-efficiency purification technology that overcomes critical issues associated with the production of clinical-quality exosomes as delivery vehicles for gene-based therapeutics.
Exosomes are emerging as an effective, non-viral chassis for genetic medicines, as they are non-toxic, efficient at delivering RNA cargoes into cells and able to do so without eliciting an immune response.
Initial research efforts between BIA and Exopharm will focus on the assessment and validation of the addition of LEAP ligand chemistry to CIM monolithic columns. BIA also aims to determine the optimal immobilisation density of LEAP ligands for high-throughput, large scale production of purified exosomes.
